You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Moodys
Medtronic
Merck

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Myrcludex B

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Myrcludex B?

Myrcludex B is an investigational drug.

There have been 6 clinical trials for Myrcludex B. The most recent clinical trial was a Phase 2 trial, which was initiated on April 15th 2019.

The most common disease conditions in clinical trials are Hepatitis, Hepatitis A, and Hepatitis, Chronic. The leading clinical trial sponsors are Hepatera Ltd., MYR GmbH, and Data Matrix.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Myrcludex B
TitleSponsorPhase
Phase 2b Study to Assess Efficacy and Safety of Bulevirtide With Peginterferon Alfa-2a in Patients With CHDHepatera Ltd.Phase 2
Phase 2b Study to Assess Efficacy and Safety of Bulevirtide With Peginterferon Alfa-2a in Patients With CHDMYR GmbHPhase 2
Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis DeltaHepatera Ltd.Phase 3

See all Myrcludex B clinical trials

Clinical Trial Summary for Myrcludex B

Top disease conditions for Myrcludex B
Top clinical trial sponsors for Myrcludex B

See all Myrcludex B clinical trials

US Patents for Myrcludex B

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Myrcludex B   Start Trial Non-invasive method for assessing liver fibrosis progression CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS (Angers, FR) UNIVERSITE D'ANGERS (Angers, FR)   Start Trial
Myrcludex B   Start Trial Oligonucleotide chelate complex--polypeptide compositions and methods REPLICOR INC. (Montreal, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Myrcludex B

Drugname Country Document Number Estimated Expiration Related US Patent
Myrcludex B Australia AU2013262416 2032-05-18   Start Trial
Myrcludex B Brazil BR112014028654 2032-05-18   Start Trial
Myrcludex B Canada CA2873529 2032-05-18   Start Trial
Myrcludex B Chile CL2014003134 2032-05-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Moodys
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.